🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 98943L107
- IPO
- 4/3/2020 · $18.00/share
Business: Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. In addition to its lead program, ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative breast cancer, the Company is developing a broad pipeline of oncology candidates, targeting areas of major unmet medical need.
Company Contact
- CEO
- Julie Eastland
- CFO
- Melissa Epperly
- Headquarters
- 10275 Science Center Dr. Suite 200, San Diego, CA 92121
- Phone
- 858-263-4333
- Investor Relations
- Adam Levy · 646-378-2931 · alevy@zentalis.com